Unable to bring a pregnancy to term, Vered, thanks to her determination and perseverance and fortified with the help of the Hadassah Medical Center’s fertility specialists, eventually became the mother of three babies.
When a woman who needed dental surgery became hysterical with fear as she drove up to the hospital, unable to gain the courage to enter, Hadassah Medical Center Senior Anesthesiologist Prof. Alex Avidan and Prof. Eliezer Kauffman, Director of Dental Anesthesia, came out to her car.
As our Chanukah dreidls remind us, more than 2,000 years ago, “A great miracle happened here.” But here at Hadassah, great miracles happen every day--so many, in fact, that I had a hard time choosing which to tell you about.
A clinical trial with TL-118 --a new treatment for metastatic pancreatic cancer--that has been ongoing at the Hadassah University Medical Center and three other oncology centers in Israel, has been expanded to the United States.
Dr. Itai Berger, Director of Hadassah’s Pediatric Neuro-Cognitive Center, and his team have created a model for early diagnosis and intervention with children who suffer from Attention Deficit Hyperactivity Disorder (ADHD) or Learning Disabilities (LD,) which is being piloted in the Jerusalem school system.
Dr. Ezekiel Landau, Director of the Pediatric Urology Department at the Hadassah University Medical Center, recently joined his surgical colleagues in the operating room at Cincinnati (Ohio) Children’s Hospital Medical Center as part of an ongoing collaboration between the two medical institutions.
The Hadassah University Medical Center, for the first time in Israel, has pioneered a new treatment for liver cancer, using a direct flow of high-voltage electric current to destroy a malignant tumor.
Enlivex – a Hadasit start-up company (under HBL) which develops a preventive immune-modulatory treatment invented by Prof. Dror Mevorach and his laboratory at Hadassah Medical Center - has successfully completed the first Phase I/IIa clinical trial for testing the safety and preliminary assessment of the effectiveness of ApoCell in the prevention and treatment of graft-versus-host disease (GVHD), a devastating and potentially life-threatening complication that occurs in 50-70% of patients receiving bone-marrow transplantation.
As I write this, negotiations for a ceasefire are taking place, while rockets and missiles continue to hit Israeli cities and towns--some a considerable distance from the Gaza Strip. This is a very difficult time, a very challenging time, yet there is a hope for a better future.
The Hadassah Director of External Relations updates the role of the Hadassah Hospitals as the conflict continues in Gaza